Miller, A.A., Pang, H., Hodgson, L., Ramnath, N., Otterson, G.A., Kelley, M.J., Kratzke, R.A., Vokes, E.E. for the Cancer and Leukemia Group B (2010) A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer [Cancer and Leukemia Group B 30602]. Journal of Thoracic Oncology, 5, 380-384. http://dx.doi.org/10.1097/JTO.0b013e3181cee36e

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.